Plandai Biotechnology, Inc. Submits Request to South African Legislature to Permit Cannabis Research
March 24 2014 - 9:00AM
Marketwired
Plandai Biotechnology, Inc. Submits Request to South African
Legislature to Permit Cannabis Research
Proposal Submitted to Parliament on Plandaí's Behalf by Dr.
Mario Oriani-Ambrosini, Legislator and Cannabis Advocate
SEATTLE, WA--(Marketwired - Mar 24, 2014) - Plandaí
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutriceutical, and pharmaceutical, today announced the
submission of a request for ministerial dispensation to the
Secretary of Parliament of South Africa to permit cannabis research
in South Africa for medicinal purposes. Dr. Mario
Oriani-Ambrosini, a South African legislator battling terminal
cancer, recently introduced legislation to permit medical marijuana
research and usage that has generated a groundswell of popular
support and led to the formation of The Cancer Treatment
Campaign.
Dr. Oriani-Ambrosini, who has incurable cancer of the pleura,
has sought inter alia via the Medical Innovations Bill to
legalize the medicinal and industrial applications of the cannabis
plant. Plandaí and the Cancer Treatment Campaign, together
with Dr. Oriani-Ambrosini, are seeking a special ministerial
dispensation to pursue methods of delivering a clinical dose of
non-psychoactive nano-particle cannabinoid molecules. The
proposed collective collaborative research project will be
conducted by the universities of Cape Town, Mississippi, Alabama
and North West, Potchefstroom, making this a uniquely
African-American fight against the world scourge of cancer.
Plandaí's live-plant extraction process recovers phytonutrients
from plant material in a mainly nano particle form and rearranges
the antioxidants (polyenes) into a format bio-compatible with
humans and animals. In addition, through Plandaí's agreement with
North West University, South Africa, the company holds the world
license to the Pheroid® patented entrapment system to deliver
protected Phytofare™ antioxidants to the white blood cells. The
result of these two combined technologies is the ability to finally
deliver a clinical, pharmaceutical grade dose of cannabinoids to
human tissues, thereby unlocking the promise of using natural
products to fight many of mankind's most elusive and deadly
diseases.
Apart from the well-known medical benefits of cannabis, such as
reducing nausea, improving appetite, and reducing anxiety,
cannabinoids have shown promise in multiple studies for treating
various cancers, epilepsy, pain relief, and in neurological
diseases including Alzheimer's, Parkinson's, dementia, and Multiple
Sclerosis.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandaí Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South Africa, to producing its patented
Phytofare™ extracts in-house, allowing the Company to guarantee the
continuity of supply as well as quality control throughout the
entire process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please
visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandaí's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandaí is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact: Andrew Beyer Phone: 619-202-7456
Email: investor@Plandaíbiotech.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Sep 2023 to Sep 2024